Oral KT-621 for moderate to severe eosinophilic asthma
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This trial tests an oral medication called KT-621 for people with moderate to severe eosinophilic asthma. It aims to see if the drug can help control asthma better than the standard inhaled treatments alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have had asthma for at least 1 year.
- You take a medium or high dose inhaled steroid (ICS) plus a long-acting bronchodilator (LABA) every day.
- You have had at least 1 asthma flare-up in the past year that needed oral steroids or a hospital visit.
- Your FeNO (a measure of airway inflammation) is at least 25 parts per billion, and your blood eosinophil count is at least 0.30 × 10^9/L.
- You are not a current smoker and have not smoked for at least 6 months, and you have a limited smoking history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new nasal spray (AD17002) for people with moderate to severe eosinophilic asthma, a type of asthma with high eosinophil blood cells. The spray is self-administered at home, and the study aims to see if it is safe and helps control asthma.
This study tests a new medicine called GB-0895 for people with severe asthma that is not well controlled by current treatments. The medicine is added to your usual asthma medications to see if it can reduce asthma attacks and improve breathing.
This study tests an investigational medicine called tilrekimig for people with severe asthma that isn't well controlled. It aims to reduce asthma attacks and improve breathing.
This study tests a new add-on medicine called GB-0895 for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this medicine can reduce asthma attacks and improve breathing.
This study tests a new medicine called tozorakimab for adults whose asthma is not well controlled despite using their usual inhalers. It aims to see if it can reduce asthma attacks and improve symptoms.
This trial is for people with asthma who already completed a previous study of the drug KT-621. It aims to see if taking KT-621 for a longer time is safe and helpful.
Hear when a new Eosinophilic Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.